{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:52:22Z","timestamp":1794293542655,"version":"4.9.0"},"reference-count":32,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Molecular classification has transformed risk stratification in endometrial cancer, providing prognostic information beyond traditional clinicopathologic features. However, the relationship between molecular subtype, nodal involvement, and recurrence risk remains incompletely defined. This study aimed to compare lymph node metastasis rates across molecular subgroups and evaluate survival outcomes and prognostic factors for recurrence. Methods: We conducted a retrospective study including 158 patients with a preoperative diagnosis of presumed early-stage endometrial carcinoma treated surgically between 2021 and 2024. Molecular classification was performed according to WHO criteria, including POLE-ultramutated, mismatch repair deficient (MMRd), p53-abnormal (p53-abn), and no specific molecular profile (NSMP). Sentinel lymph node biopsy (SLNB) was the primary method for nodal staging. Survival outcomes were assessed using a Kaplan\u2013Meier analysis, and logistic regression was used to identify prognostic factors for recurrence. Results: NSMP was the most frequent molecular subtype (44.3%), followed by MMRd (29.1%), p53-abn (20.9%), and POLE-mutated tumors (5.7%). Overall, 11.4% of patients had nodal metastases, most commonly in the p53-abn subgroup, which showed significantly higher rates of positive sentinel lymph nodes (p = 0.010). Prognosis differed significantly across molecular subtypes. POLE-mutated and NSMP tumors demonstrated the most favorable outcomes, while p53-abn tumors showed the poorest overall survival and progression-free survival. In a univariate analysis, grade, lymphovascular space invasion (LVSI), myometrial invasion, FIGO stage, and molecular classification were associated with recurrence. Stratified analyses suggested LVSI as the most relevant prognostic factor within the MMRd subgroup. Conclusions: Molecular classification is strongly associated with nodal involvement and survival outcomes in early-stage endometrial cancer. Integrating molecular subtype with clinicopathologic factors may improve recurrence risk stratification and guide individualized surgical and adjuvant treatment strategies.<\/jats:p>","DOI":"10.3390\/cancers18101628","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:40:31Z","timestamp":1779115231000},"page":"1628","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Classification as a Predictor of Nodal Involvement and Survival Outcomes in Presumed Early-Stage Endometrial Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Irene","family":"Pellicer","sequence":"first","affiliation":[{"name":"Gynecologic Oncology Department, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9311-8327","authenticated-orcid":false,"given":"Blanca","family":"Diaz","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Department, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5901-1730","authenticated-orcid":false,"given":"Mar\u00eda","family":"Esp\u00edas-Alonso","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Department, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9175-7767","authenticated-orcid":false,"given":"Ignacio","family":"Zapardiel","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Department, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-5270","authenticated-orcid":false,"given":"Myriam","family":"Gracia","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Department, La Paz University Hospital, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: Update","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_3","first-page":"308","article-title":"Cancer treatment and survivorship statistics","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/AOG.0000000000006080","article-title":"Molecular Characterization and Clinical Implications of Endometrial Cancer","volume":"146","author":"Secord","year":"2025","journal-title":"Obstet. Gynecol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., and Shen, R. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373. Erratum in Nature 2013, 500, 242.","DOI":"10.1038\/nature12325"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102107","DOI":"10.1016\/j.ijgc.2025.102107","article-title":"Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer","volume":"35","author":"Slomovitz","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ferrari, F., Gozzini, E., Torroni, L., Rota, M., Soleymani Majd, H., Dell\u2019Avalle, C., Alberto, F.F., and Odicino, F. (2025). Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: A systematic review and meta-analysis. Am. J. Obstet. Gynecol., Epub ahead of printing.","DOI":"10.1016\/j.ajog.2025.09.041"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(25)00379-1","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial","volume":"26","author":"Post","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN Guidelines\u00ae Insights: Uterine Neoplasms, Version 3.2025","volume":"23","author":"Campos","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","article-title":"A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): A multicentre, prospective, cohort study","volume":"18","author":"Rossi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijgo.70206","article-title":"Integration of sentinel node mapping and molecular classification in endometrial cancer staging","volume":"171","author":"Bogani","year":"2025","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1136\/ijgc-2024-005672","article-title":"Impact of molecular classification on recurrence risk in endometrial cancer patients with lymph node metastasis: Multicenter retrospective study","volume":"34","author":"Schivardi","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2024.09.012","article-title":"Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping","volume":"191","author":"Praiss","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/ijgc-2024-005711","article-title":"SENECA study: Staging endometrial cancer based on molecular classification","volume":"34","author":"Chacon","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_16","unstructured":"WHO Classification of Tumours Editorial Board (2023). Female Genital Tumours, International Agency for Research on Cancer (IARC). [6th ed.]."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.5858\/arpa.2019-0249-RA","article-title":"Pathologic protocols for sentinel lymph nodes ultrastaging in cervical cancer","volume":"144","author":"Dundr","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy","volume":"38","author":"Powell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer: A TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100085","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.6004\/jnccn.2022.7096","article-title":"Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice","volume":"21","author":"Jamieson","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1470-2045(11)70070-5","article-title":"Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer (SENTI-ENDO)","volume":"12","author":"Ballester","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1007\/s12094-024-03401-y","article-title":"Molecular profile in endometrial carcinoma: Can we predict the lymph node status? A systematic review and meta-analysis","volume":"26","author":"Bebia","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ygyno.2024.07.003","article-title":"Molecular classification improves preoperative risk assessment of endometrial cancer","volume":"189","author":"Cabrera","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/ijgc-2024-005416","article-title":"Predicting the risk of nOdal disease with histological and molecular features in endometrial cancer: The prospective PROME trial","volume":"34","author":"Bogani","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ijgc-2023-004289","article-title":"Improving endometrial cancer assessment by combining the new techniqUe of GENomic profiling with surgical extra uterIne disEase assessment (EUGENIE)","volume":"33","author":"Kasius","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PGP.0000000000001112","article-title":"Clinicopathological and Molecular Characterization of High Grade Endometrial Carcinomas of No Specific Molecular Profile (NSMP) Stratified by ER Status","volume":"45","author":"Timmermans","year":"2025","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"FIGO Committee on Gynecologic Oncology (2023). FIGO staging of endometrial cancer: 2023 revision. Int. J. Gynecol. Obstet., 162, 383\u2013394.","DOI":"10.1002\/ijgo.14923"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2025.01.006","article-title":"Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258","volume":"193","author":"Clements","year":"2025","journal-title":"Gynecol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1628\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:57:57Z","timestamp":1779116277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101628"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101628","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}